AR046081A1 - Inhibidores heterociclicos de mek y uso de los mismos - Google Patents
Inhibidores heterociclicos de mek y uso de los mismosInfo
- Publication number
- AR046081A1 AR046081A1 ARP040103151A ARP040103151A AR046081A1 AR 046081 A1 AR046081 A1 AR 046081A1 AR P040103151 A ARP040103151 A AR P040103151A AR P040103151 A ARP040103151 A AR P040103151A AR 046081 A1 AR046081 A1 AR 046081A1
- Authority
- AR
- Argentina
- Prior art keywords
- heteroaryl
- aryl
- heterocyclyl
- arylalkyl
- alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 39
- 125000001072 heteroaryl group Chemical group 0.000 abstract 30
- 125000003118 aryl group Chemical group 0.000 abstract 28
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 26
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 20
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 15
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 12
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 12
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 12
- 125000005843 halogen group Chemical group 0.000 abstract 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 12
- 125000003342 alkenyl group Chemical group 0.000 abstract 10
- 125000000304 alkynyl group Chemical group 0.000 abstract 10
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 8
- 125000002837 carbocyclic group Chemical group 0.000 abstract 8
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 6
- 125000004429 atom Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000004043 oxo group Chemical group O=* 0.000 abstract 5
- 229920006395 saturated elastomer Polymers 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a heterocíclicos útiles en el tratamiento de los desórdenes proliferativos. Reivindicación 1: Un compuesto de la fórmula (1), y sus sales, profármacos y solvatos farmacéuticamente aceptables, en donde: R1, R2, R7, R8, R9 y R10 son, de modo independiente, hidrógeno, halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, - NR3R4, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, -S(O)j(alquilo C1-6), -S(O)j(CR4R5)m-arilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, -O(CR4R5)m- arilo, -NR4(CR4R5)m-arilo, -O(CR4R5)m-heteroarilo, -NR4(CR4R5)m-heteroarilo, -O(CR4R5)m-heterociclilo o -NR4(CR4R5)m-heterociclilo, en donde cualquiera de dichas porciones alquilo, alquenilo, alquinilo, cicloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo están opcionalmente sustituidas con uno o varios grupos seleccionados, de modo independiente, de oxo, halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, - SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo; R3 es hidrógeno, trifluorometilo, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, fosfato o un residuo de aminoácido, en donde cualquiera de dichas porciones alquilo, alquenilo, alquinilo, cicloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo están opcionalmente sustituidas con uno o varios grupos seleccionados, de modo independiente, de oxo, halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SR', -S(O)R'''', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo, o R3 y R4 juntos, con el átomo al que están unidos, forman un anillo carbocíclico, heteroarilo o heterocíclico de 4 a 10 miembros, en donde cualquiera de dichos anillos carbocíclico, heteroarilo o heterocíclico están opcionalmente sustituidos con uno o varios grupos seleccionados, de modo independiente, de halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR'SO2R'''', - SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo; R', R'' y R''' son, de modo independiente, hidrógeno, alquilo inferior, alquenilo inferior, arilo y arilalquilo y R'''' es alquilo inferior, alquenilo inferior, arilo y arilalquilo, o dos de R', R'', R''' o R'''' juntos, con el átomo al que están unidos, forman un anillo carbocíclico, heteroarilo o heterocíclico de 4 a 10 miembros, en donde cualquiera de dichos anillos alquilo, alquenilo, arilo, arilalquilo, anillos carbocíclicos, anillos heteroarilo o anillos heterocíclicos están opcionalmente sustituidos con halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo; R4 y R5 son, de modo independiente, hidrógeno o alquilo C1-6, o R4 y R5 juntos, con el átomo al que están unidos, forman un anillo carbocíclico, heteroarilo o heterocíclico de 4 a 10 miembros, en donde dicho alquilo o cualquiera de dichos anillos carbocíclicos, heteroarilo y heterocíclicos están opcionalmente sustituidos con uno o varios grupos seleccionados, de modo independiente, de halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R'''', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', - NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo; R6 es trifluorometilo, alquilo C1-10, cicloalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, en donde cualquiera de dichas porciones alquilo, cicloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo están opcionalmente sustituidas con uno o varios grupos seleccionados, de modo independiente, de oxo, halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', - NR'R', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo; W es heteroarilo, heterociclilo, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(cicloalquilo C3-10), - C(O)(alquilo C1-10), -C(O)(arilo), -C(O)(heteroarilo), -C(O)(heterociclilo) y CR3OR3 en donde cualquiera de dichos heteroarilo, heterociclilo, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(cicloalquilo C3-10), -C(O)(alquilo C1-10), - C(O)(arilo), -C(O)(heteroarilo), y -C(O)(heterociclilo), CR3OR3 están opcionalmente sustituidos con uno o varios grupos seleccionados, de modo independiente, de -NR3R4, -OR3, -R2, alquilo C1-10, alquenilo C2-10 y alquinilo C2-10, en donde cualquiera de dichos alquilo C1-10, alquenilo C2-10 y alquinilo C2-10 están opcionalmente sustituidos con 1 o varios grupos seleccionados, de modo independiente, de -NR3R4 y -OR3; m es 0, 1, 2, 3, 4 ó 5; y j es 0, 1 ó 2. Reivindicación 21: Un compuesto de la fórmula (2), y sus sales, profármacos y solvatos farmacéuticamente aceptables, en donde: R1, R2, R7, R8, R9, R10 y R11 se seleccionan, de modo independiente, de hidrógeno, halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, - OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, -S(O)j(alquilo C1-6), - S(O)j(CR4R5)m-arilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, -O(CR4R5)m-arilo, -NR4(CR4R5)m-arilo, -O(CR4R5)m-heteroarilo, -NR4(CR4R5)m-heteroarilo, -O(CR4R5)m-heterociclilo o -NR4(CR4R5)m- heterociclilo, en donde cualquiera de dichas porciones alquilo, alquenilo, alquinilo, cicloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo están opcionalmente sustituidas con uno o varios grupos seleccionados, de modo independiente, de oxo, halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, - NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo; o R7 y R11, junto con los átomos a los que están unidos, forman un anillo carbocíclico o heterocíclico saturado, insaturado o parcialmente saturado de 4 a 10 miembros, en donde cualquiera de dichos anillos carbocíclicos o heterocíclicos saturados, insaturados o parcialmente saturados están opcionalmente sustituidos con uno o varios grupos seleccionados, de modo independiente, de halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR´C(NCN)NR''R''', -OR', arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo; R3 se selecciona de hidrógeno, trifluorometilo, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, fosfato o un residuo de aminoácido, en donde cualquiera de dichas porciones alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo están opcionalmente sustituidas con uno o varios grupos seleccionados, de modo independiente, de oxo, halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR'SO2R'''', - SO2NR'R'', -C(O)R', -C(O)OR', -OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SR', -S(O)R'''', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR', arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo, o R3 y R4 juntos, con el átomo al que están unidos, forman un anillo heterocíclico saturado, insaturado o parcialmente saturado de 4 a 10 miembros, en donde cualquiera de dichos anillos heterocíclico saturados, insaturados o parcialmente saturados están opcionalmente sustituidos con uno o varios grupos seleccionados, de modo independiente, de halo, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR'SO2R'''', -SO2NR'R'', -C(O)R', -C(O)OR', - OC(O)R', -NR'C(O)OR'''', -NR'C(O)R'', -C(O)NR'R'', -SO2R'''', -NR'R'', -NR'C(O)NR''R''', -NR'C(NCN)NR''R''', -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo; R', R'' y R''' se seleccionan, de modo independiente, de hidrógeno, alquilo inferior, alquenilo inferior, arilo y arilalquilo y R'''' se selecciona de alquilo inferior, alquenilo inferior, arilo y arilalquilo, o dos de R', R'', R''' o R'''' juntos, con el átomo al que están unidos, forman un anillo heterocíclico saturado, insaturado o parcialmente saturado de 4 a 10 miembros, en donde cualquiera de dichos alquilo, alquenilo, arilo, arilalquilo,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/654,580 US7144907B2 (en) | 2003-09-03 | 2003-09-03 | Heterocyclic inhibitors of MEK and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046081A1 true AR046081A1 (es) | 2005-11-23 |
Family
ID=34218110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103151A AR046081A1 (es) | 2003-09-03 | 2004-09-02 | Inhibidores heterociclicos de mek y uso de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US7144907B2 (es) |
| EP (1) | EP1673339B1 (es) |
| JP (1) | JP4131741B2 (es) |
| KR (1) | KR20060070558A (es) |
| CN (1) | CN1874769A (es) |
| AR (1) | AR046081A1 (es) |
| AU (1) | AU2004270699B2 (es) |
| BR (1) | BRPI0414111A (es) |
| CA (1) | CA2537321A1 (es) |
| IL (4) | IL173936A (es) |
| IS (1) | IS8392A (es) |
| MX (1) | MXPA06002466A (es) |
| NO (1) | NO20061506L (es) |
| PT (1) | PT1673339E (es) |
| RU (1) | RU2006109599A (es) |
| TW (1) | TW200526607A (es) |
| WO (1) | WO2005023759A2 (es) |
| ZA (1) | ZA200602581B (es) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| EP1674452A4 (en) * | 2003-09-19 | 2007-10-10 | Chugai Pharmaceutical Co Ltd | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR |
| US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| BRPI0416692A (pt) * | 2003-11-19 | 2007-01-30 | Array Biopharma Inc | inibidores heterocìclicos de mek e métodos de emprego destes |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| ES2330872T3 (es) * | 2004-12-01 | 2009-12-16 | Merck Serono Sa | Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas. |
| KR101300831B1 (ko) * | 2005-03-21 | 2013-08-30 | 에스*바이오 피티이 리미티드 | 이미다조[1,2-ａ]피리딘 유도체, 이의 제조 방법 및 그의약학적 용도 |
| US7666880B2 (en) | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
| NZ563707A (en) * | 2005-05-18 | 2011-01-28 | Array Biopharma Inc | Heterocyclic inhibitors of MEK and methods of use thereof |
| US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| WO2006128184A2 (en) * | 2005-05-20 | 2006-11-30 | Alantos-Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
| US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7579360B2 (en) * | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| WO2007025090A2 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| AU2013203939B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| CA3052368A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors |
| AU2012261703B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| GB0616214D0 (en) * | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
| ATE531720T1 (de) * | 2006-08-21 | 2011-11-15 | Genentech Inc | Aza-benzofuranylverbindungen und anwendungsverfahren dafür |
| JP5349306B2 (ja) * | 2006-08-21 | 2013-11-20 | ジェネンテック， インコーポレイテッド | アザベンゾチオフェニル化合物および使用方法 |
| RU2444524C2 (ru) * | 2006-08-21 | 2012-03-10 | Дженентек, Инк. | Азабензотиофенильные соединения и способы применения |
| US7563797B2 (en) | 2006-08-28 | 2009-07-21 | Forest Laboratories Holding Limited | Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands |
| US8236841B2 (en) * | 2006-09-13 | 2012-08-07 | Kyowa Hakko Kirin Co., Ltd. | Fused heterocycle derivative |
| CN101621931A (zh) * | 2006-11-27 | 2010-01-06 | H.隆德贝克有限公司 | 杂芳基酰胺衍生物 |
| WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| CN101772498A (zh) * | 2007-04-10 | 2010-07-07 | H.隆德贝克有限公司 | 作为p2x7拮抗剂的杂芳基酰胺类似物 |
| SG182223A1 (en) | 2007-06-25 | 2012-07-30 | Novartis Ag | N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors |
| GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| ES2456966T3 (es) * | 2007-11-12 | 2014-04-24 | Takeda Pharmaceutical Company Limited | Inhibidores de MAPK/ERK cinasa |
| AU2008343062B2 (en) * | 2007-12-19 | 2013-03-07 | Genentech, Inc. | 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| PT2222675E (pt) | 2007-12-19 | 2013-11-13 | Genentech Inc | 5-anilinoimidazopiridinas e métodos de utilização |
| WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| CN102137847B (zh) * | 2008-07-01 | 2015-06-10 | 健泰科生物技术公司 | 作为mek激酶抑制剂的二环杂环 |
| CA2727252A1 (en) * | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Isoindolone derivatives as mek kinase inhibitors and methods of use |
| WO2010068258A1 (en) | 2008-12-08 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Imidazopyrazine syk inhibitors |
| JP5651125B2 (ja) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異 |
| ES2609767T3 (es) * | 2009-10-12 | 2017-04-24 | F. Hoffmann-La Roche Ag | Combinaciones de un inhibidor de PI3K y un inhibidor de MEK |
| ES2576061T3 (es) | 2010-02-25 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF |
| MX343368B (es) | 2010-03-09 | 2016-11-01 | The Broad Inst Inc * | Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer. |
| MX350010B (es) | 2010-03-11 | 2017-08-23 | Gilead Connecticut Inc | Inhibidores syk de imidazopiridinas. |
| US9173887B2 (en) | 2010-12-22 | 2015-11-03 | Abbvie Inc. | Hepatitis C inhibitors and uses thereof |
| UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| CN103204822B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途 |
| EP2833889B1 (en) | 2012-04-04 | 2017-11-01 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| WO2013178581A1 (en) | 2012-05-31 | 2013-12-05 | Bayer Pharma Aktiengesellschaft | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients |
| PT2884979T (pt) | 2012-08-17 | 2019-09-04 | Hoffmann La Roche | Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib |
| TR201807861T4 (tr) | 2012-10-12 | 2018-06-21 | Exelixis Inc | Kanser tedavisinde kullanım için bileşikler yapmak için yeni işlem. |
| UA111925C2 (uk) | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| WO2014151900A1 (en) | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| SG11201507730UA (en) | 2013-03-21 | 2015-10-29 | Novartis Ag | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
| EP3094736A4 (en) | 2014-01-14 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| CN103980217B (zh) * | 2014-05-26 | 2015-12-30 | 南京林业大学 | 一类蒎烷基异噁唑类化合物及其合成方法和应用 |
| US20170248603A1 (en) | 2014-10-06 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response |
| MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| RU2638155C1 (ru) * | 2016-02-29 | 2017-12-12 | Общество С Ограниченной Ответственностью "Сай Фарма" | Производные бензо[d]изоксазола и их применение |
| CN107759532B (zh) * | 2017-11-23 | 2021-02-12 | 苏州大学 | 一种苯并噁唑-2-乙基肟衍生物、其制备方法及应用 |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| PE20231651A1 (es) | 2020-06-09 | 2023-10-17 | Array Biopharma Inc | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf |
| JP2024521788A (ja) | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | 併用療法 |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| EP0602242A4 (en) | 1991-08-22 | 1994-06-29 | Yoshitomi Pharmaceutical | Benzisoxazole compound and use thereof. |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| EP0710654A4 (en) | 1993-07-23 | 1996-08-28 | Green Cross Corp | TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE |
| US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| MX9708026A (es) | 1995-04-20 | 1997-11-29 | Pfizer | Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos. |
| DE19517448A1 (de) | 1995-05-12 | 1996-11-14 | Thomae Gmbh Dr K | Neue Benzothiazole und Benzoxazole, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| IL127567A0 (en) | 1996-07-18 | 1999-10-28 | Pfizer | Phosphinate based inhibitors of matrix metalloproteases |
| JP2000501423A (ja) | 1996-08-23 | 2000-02-08 | ファイザー インク． | アリールスルホニルアミノヒドロキサム酸誘導体 |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| ES2202796T3 (es) | 1997-02-03 | 2004-04-01 | Pfizer Products Inc. | Derivados de acidos arilsulfonilaminohidroxamicos. |
| EP0966438A1 (en) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| CA2280151C (en) | 1997-02-11 | 2005-12-13 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6821963B2 (en) * | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| JP2002511092A (ja) | 1997-07-01 | 2002-04-09 | ワーナー−ランバート・コンパニー | ４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用 |
| US6506798B1 (en) * | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
| AU756586C (en) | 1997-07-01 | 2004-01-29 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| DE69924641D1 (de) | 1999-01-07 | 2005-05-12 | Warner Lambert Company Llc Mor | Behandlung von asthma anhand von mek-inhibitoren |
| CA2358438A1 (en) | 1999-01-07 | 2000-07-13 | David Thomas Dudley | Antiviral method using mek inhibitors |
| AU2203700A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Benzoheterocycles and their use as mek inhibitors |
| WO2000042002A1 (en) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| JP2000204079A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| JP2002534446A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | ４′ヘテロアリールジアリールアミン |
| WO2000042003A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| WO2000042029A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| EP1202726A2 (en) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Method for treating chronic pain using mek inhibitors |
| IL147617A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| KR20020015376A (ko) | 1999-07-16 | 2002-02-27 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법 |
| US7030119B1 (en) | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
| TR200200205T2 (tr) | 1999-07-16 | 2002-06-21 | Warner-Lambert Company | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi |
| MXPA02008103A (es) | 2000-03-15 | 2002-11-29 | Warner Lambert Co | Diarilaminas sustituidas con 5-amida como inhibidores mek. |
| US6960614B2 (en) | 2000-07-19 | 2005-11-01 | Warner-Lambert Company | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids |
| MXPA03001654A (es) | 2000-08-25 | 2004-09-10 | Warner Lambert Co | Proceso para la elaboracion del acido n-aril-antranilico y sus derivados. |
| US20020052373A1 (en) * | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| JP2004514718A (ja) | 2000-11-02 | 2004-05-20 | アストラゼネカ アクチボラグ | 抗癌剤としての置換キノリン類 |
| US6748692B2 (en) * | 2001-10-23 | 2004-06-15 | Travis Sprouse | Spinner bait |
| MXPA04008893A (es) * | 2002-03-13 | 2005-06-20 | Array Biopharma Inc | Derivados de bencimidazol n3 alquilados como inhibidores de mek. |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| JP2005526076A (ja) | 2002-03-13 | 2005-09-02 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋ阻害剤としてのｎ３アルキル化ベンズイミダゾール誘導体 |
| US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
-
2003
- 2003-09-03 US US10/654,580 patent/US7144907B2/en not_active Expired - Fee Related
-
2004
- 2004-08-30 US US10/929,295 patent/US7230099B2/en not_active Expired - Fee Related
- 2004-09-01 PT PT47830286T patent/PT1673339E/pt unknown
- 2004-09-01 JP JP2006525449A patent/JP4131741B2/ja not_active Expired - Fee Related
- 2004-09-01 CN CNA2004800326551A patent/CN1874769A/zh active Pending
- 2004-09-01 ZA ZA200602581A patent/ZA200602581B/en unknown
- 2004-09-01 AU AU2004270699A patent/AU2004270699B2/en not_active Ceased
- 2004-09-01 RU RU2006109599/04A patent/RU2006109599A/ru not_active Application Discontinuation
- 2004-09-01 EP EP04783028.6A patent/EP1673339B1/en not_active Expired - Lifetime
- 2004-09-01 KR KR1020067004505A patent/KR20060070558A/ko not_active Withdrawn
- 2004-09-01 WO PCT/US2004/028649 patent/WO2005023759A2/en not_active Ceased
- 2004-09-01 CA CA002537321A patent/CA2537321A1/en not_active Abandoned
- 2004-09-01 BR BRPI0414111-3A patent/BRPI0414111A/pt not_active IP Right Cessation
- 2004-09-01 MX MXPA06002466A patent/MXPA06002466A/es not_active Application Discontinuation
- 2004-09-02 AR ARP040103151A patent/AR046081A1/es not_active Application Discontinuation
- 2004-09-02 TW TW093126520A patent/TW200526607A/zh unknown
-
2006
- 2006-02-26 IL IL173936A patent/IL173936A/en not_active IP Right Cessation
- 2006-03-31 IS IS8392A patent/IS8392A/is unknown
- 2006-04-03 NO NO20061506A patent/NO20061506L/no not_active Application Discontinuation
- 2006-04-24 US US11/410,343 patent/US7271178B2/en not_active Expired - Fee Related
- 2006-04-24 US US11/410,336 patent/US7511058B2/en not_active Expired - Fee Related
- 2006-04-24 US US11/410,344 patent/US20060189668A1/en not_active Abandoned
-
2012
- 2012-05-08 IL IL219669A patent/IL219669A0/en unknown
- 2012-05-08 IL IL219670A patent/IL219670A/en not_active IP Right Cessation
- 2012-05-08 IL IL219671A patent/IL219671A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046081A1 (es) | Inhibidores heterociclicos de mek y uso de los mismos | |
| AR038972A1 (es) | Derivados de bencimidazol n3 alquilado como inhibidores de mek | |
| AR051248A1 (es) | Derivados de 3-arilamino piridina | |
| AR038971A1 (es) | Derivados de bencimidazol n3 alquilado como inhibidores de mek | |
| RS51861B (sr) | Heterociklični inhibitori mek-a | |
| AR045738A1 (es) | Derivados de bencimidazol n3 alquilados como inhibidores de mek | |
| RU2348617C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| CO2021003298A2 (es) | Compuestos de sulfonamidaurea novedosos | |
| DK1313695T3 (da) | Estere af 5-aminolevulinsyre som fotosensibiliserende midler i fotokemoterapi | |
| BR0308816A (pt) | Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| MY144607A (en) | Macrocylic inhibitors of hepatitis c virus | |
| CO5680479A2 (es) | Derivados de pirimidilsulfonamida como moduladores del receptor de quimiocina, sus composiciones y proceso de obtencion | |
| AR016499A1 (es) | Compuestos de pirrolo[2,3-d]pirimidina, composiciones y procesos para su uso en medicina. | |
| PT822186E (pt) | L-tert-leucina-2-piridilamida | |
| RU2010105678A (ru) | Гетероциклические амидные соединения как ингибиторы протеинкиназ | |
| AR044403A1 (es) | Derivados de oximas y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
| DE602004031258D1 (de) | Polycyclische mittel zur behandlung von infektione | |
| AR037181A1 (es) | Compuesto de 4-heteroaril-(5-miembros) acil pirrolidina, formulacion farmaceutica que lo comprende, uso del mismo para preparar un medicamento y procedimiento para su preparacion | |
| CO5700776A2 (es) | Compuestos utiles para el tratamiento de enfermedades | |
| ATE421321T1 (de) | Methoden zur behandlung von angstzuständen | |
| AR040489A1 (es) | Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen | |
| AR038404A1 (es) | Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye | |
| AR041297A1 (es) | Derivados de 4-pirrolidino- fenil- bencil eter | |
| AR052682A1 (es) | DERIVADOS DE 5, 6, 7, 8 - TETRAHIDROTIEN[2, 3 - B]QUINOLINA uTILES PARA INHIBIR LA ACTIVIDAD DE QUINESINA DE KSP, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |